Clinical and genetic studies of familial hemophagocytic lymphohistiocytosis in Oman: Need for early treatment

Zakia Al-Lamki, Yasser A. Wali, Anil Pathare, K. G. Ericson, Jan Inge Henter

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Hemophagocytic lymphohistiocytosis (HLH) embraces the frequently indistinguishable conditions of familial heinophagocytic lymphohistiocytosis (FHL) and virus-associated hemophagocytic syndrome (VAHS). Without therapy FHL is invariably fatal, but successful therapy, including chemotherapy and immunotherapy followed by bone marrow transplantation (BMT), has been presented. To clarify the outcome of HLH in a developing country, with regard to clinical, laboratory, and genetic features, a nationwide study on all patients diagnosed with HLH in Oman during the 5-year period 1997-2001 was performed. In 5 patients and their families, mutational analysis was made. Thirteen patients with HLH were identified, 5 of whom had clinical manifestations of central nervous system involvement at presentation. In none of the patients could an infectious cause be identified. Ten children were referred late in the disease course, and the concern about starting chemotherapy before exclusion of an acute viral infection resulted in delayed treatment in some patients. Two children were started early on the HLH-94-therapy followed by successful BMT in one child. In the successfully transplanted child, the response to intrathecal hydrocortisone appeared to be better than standard therapy with intrathecal methotrexate. Finally, a novel missense mutation in the perforin gene was identified in 2 patients and their family members, causing a transition of proline to threonine at codon 89. Early diagnosis and treatment is important to improve outcome. Intrathecal corticosteroids may be considered, in addition to intrathecal methotrexate, in certain patients. Since the novel perforin mutation has been reported in only 2 patients from Oman, and since similar polymorphism in the sequencing data of the members of their families has been identified, a founder effect is possible in this population.

Original languageEnglish
Pages (from-to)603-609
Number of pages7
JournalPediatric Hematology and Oncology
Volume20
Issue number8
Publication statusPublished - Dec 2003

Fingerprint

Oman
Hemophagocytic Lymphohistiocytosis
Chemotherapy
Bone
Clinical laboratories
Cortisol
Neurology
Polymorphism
Viruses
Developing countries
Genes
Perforin
Therapeutics
Bone Marrow Transplantation
Methotrexate
Founder Effect
Drug Therapy
Clinical Studies
Virus Diseases
Missense Mutation

Keywords

  • Children
  • Genetic
  • Hemophagocytic syndrome
  • Oman
  • Perforin

ASJC Scopus subject areas

  • Cancer Research
  • Management of Technology and Innovation
  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this

Clinical and genetic studies of familial hemophagocytic lymphohistiocytosis in Oman : Need for early treatment. / Al-Lamki, Zakia; Wali, Yasser A.; Pathare, Anil; Ericson, K. G.; Henter, Jan Inge.

In: Pediatric Hematology and Oncology, Vol. 20, No. 8, 12.2003, p. 603-609.

Research output: Contribution to journalArticle

@article{d7ae2b4685e648fb8a563d59ab374eff,
title = "Clinical and genetic studies of familial hemophagocytic lymphohistiocytosis in Oman: Need for early treatment",
abstract = "Hemophagocytic lymphohistiocytosis (HLH) embraces the frequently indistinguishable conditions of familial heinophagocytic lymphohistiocytosis (FHL) and virus-associated hemophagocytic syndrome (VAHS). Without therapy FHL is invariably fatal, but successful therapy, including chemotherapy and immunotherapy followed by bone marrow transplantation (BMT), has been presented. To clarify the outcome of HLH in a developing country, with regard to clinical, laboratory, and genetic features, a nationwide study on all patients diagnosed with HLH in Oman during the 5-year period 1997-2001 was performed. In 5 patients and their families, mutational analysis was made. Thirteen patients with HLH were identified, 5 of whom had clinical manifestations of central nervous system involvement at presentation. In none of the patients could an infectious cause be identified. Ten children were referred late in the disease course, and the concern about starting chemotherapy before exclusion of an acute viral infection resulted in delayed treatment in some patients. Two children were started early on the HLH-94-therapy followed by successful BMT in one child. In the successfully transplanted child, the response to intrathecal hydrocortisone appeared to be better than standard therapy with intrathecal methotrexate. Finally, a novel missense mutation in the perforin gene was identified in 2 patients and their family members, causing a transition of proline to threonine at codon 89. Early diagnosis and treatment is important to improve outcome. Intrathecal corticosteroids may be considered, in addition to intrathecal methotrexate, in certain patients. Since the novel perforin mutation has been reported in only 2 patients from Oman, and since similar polymorphism in the sequencing data of the members of their families has been identified, a founder effect is possible in this population.",
keywords = "Children, Genetic, Hemophagocytic syndrome, Oman, Perforin",
author = "Zakia Al-Lamki and Wali, {Yasser A.} and Anil Pathare and Ericson, {K. G.} and Henter, {Jan Inge}",
year = "2003",
month = "12",
language = "English",
volume = "20",
pages = "603--609",
journal = "Pediatric Hematology and Oncology",
issn = "0888-0018",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Clinical and genetic studies of familial hemophagocytic lymphohistiocytosis in Oman

T2 - Need for early treatment

AU - Al-Lamki, Zakia

AU - Wali, Yasser A.

AU - Pathare, Anil

AU - Ericson, K. G.

AU - Henter, Jan Inge

PY - 2003/12

Y1 - 2003/12

N2 - Hemophagocytic lymphohistiocytosis (HLH) embraces the frequently indistinguishable conditions of familial heinophagocytic lymphohistiocytosis (FHL) and virus-associated hemophagocytic syndrome (VAHS). Without therapy FHL is invariably fatal, but successful therapy, including chemotherapy and immunotherapy followed by bone marrow transplantation (BMT), has been presented. To clarify the outcome of HLH in a developing country, with regard to clinical, laboratory, and genetic features, a nationwide study on all patients diagnosed with HLH in Oman during the 5-year period 1997-2001 was performed. In 5 patients and their families, mutational analysis was made. Thirteen patients with HLH were identified, 5 of whom had clinical manifestations of central nervous system involvement at presentation. In none of the patients could an infectious cause be identified. Ten children were referred late in the disease course, and the concern about starting chemotherapy before exclusion of an acute viral infection resulted in delayed treatment in some patients. Two children were started early on the HLH-94-therapy followed by successful BMT in one child. In the successfully transplanted child, the response to intrathecal hydrocortisone appeared to be better than standard therapy with intrathecal methotrexate. Finally, a novel missense mutation in the perforin gene was identified in 2 patients and their family members, causing a transition of proline to threonine at codon 89. Early diagnosis and treatment is important to improve outcome. Intrathecal corticosteroids may be considered, in addition to intrathecal methotrexate, in certain patients. Since the novel perforin mutation has been reported in only 2 patients from Oman, and since similar polymorphism in the sequencing data of the members of their families has been identified, a founder effect is possible in this population.

AB - Hemophagocytic lymphohistiocytosis (HLH) embraces the frequently indistinguishable conditions of familial heinophagocytic lymphohistiocytosis (FHL) and virus-associated hemophagocytic syndrome (VAHS). Without therapy FHL is invariably fatal, but successful therapy, including chemotherapy and immunotherapy followed by bone marrow transplantation (BMT), has been presented. To clarify the outcome of HLH in a developing country, with regard to clinical, laboratory, and genetic features, a nationwide study on all patients diagnosed with HLH in Oman during the 5-year period 1997-2001 was performed. In 5 patients and their families, mutational analysis was made. Thirteen patients with HLH were identified, 5 of whom had clinical manifestations of central nervous system involvement at presentation. In none of the patients could an infectious cause be identified. Ten children were referred late in the disease course, and the concern about starting chemotherapy before exclusion of an acute viral infection resulted in delayed treatment in some patients. Two children were started early on the HLH-94-therapy followed by successful BMT in one child. In the successfully transplanted child, the response to intrathecal hydrocortisone appeared to be better than standard therapy with intrathecal methotrexate. Finally, a novel missense mutation in the perforin gene was identified in 2 patients and their family members, causing a transition of proline to threonine at codon 89. Early diagnosis and treatment is important to improve outcome. Intrathecal corticosteroids may be considered, in addition to intrathecal methotrexate, in certain patients. Since the novel perforin mutation has been reported in only 2 patients from Oman, and since similar polymorphism in the sequencing data of the members of their families has been identified, a founder effect is possible in this population.

KW - Children

KW - Genetic

KW - Hemophagocytic syndrome

KW - Oman

KW - Perforin

UR - http://www.scopus.com/inward/record.url?scp=0344875172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344875172&partnerID=8YFLogxK

M3 - Article

C2 - 14578030

AN - SCOPUS:0344875172

VL - 20

SP - 603

EP - 609

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 8

ER -